ARO-ANG3 is a subcutaneously administered RNA interference -based investigational medicine targeting angiopoietin like protein 3 (ANGPTL3) being developed for the treatment of dyslipidemias, such as HoFH, and metabolic diseases.
(20) Humans who have inherited genetic mutations that result in lower levels of the ANGPTL3 form of ANGPTL have been shown to have less triglyceride and LDL cholesterol in their blood, as well as an approximate one-third reduction in odds of coronary artery disease.
the lipid profiles improved with large reductions in serum triglycerides and cholesterol and large increases in HDL and in dose ranging studies of ARO-ANG3 in wild type mice, reductions in serum ANGPTL3 and liver mRNA were similar, indicating that the observed knockdown of serum ANGPTL3 is a direct result of the expected RNAi effect.
A new antisense inhibitor to angiopoietinlike protein 3 (ANGPTL3) reduces lipids in healthy adults with elevated triglyceride levels, according to results of a phase I/IIa ascending-dose trial reported at the American Heart Association scientific sessions.
In Quagliarini et al.'s study, plasma TG (triglyceride) level did not change in mice expressing ANGPTL3 alone, whereas coexpression with ANGPTL8 resulted in hypertriglyceridemia, despite a reduction in circulating ANGPTL3 .
The team of Zhang and Zheng, known for their discoveries on the role of ANGPTL2 in hematopoietic cell proliferation  and ANGPTL2 receptor LILRB2 , recently elegantly demonstrated that secretory proteins produced by HSC, such as ANGPTL2, ANGPTL3, and thrombopoietin, undergo exosomal maturation and release that is controlled by a vacuolar sorting protein VPS33B .